The value of SPECT/CT fusion imaging for post-implantation dose verification of 125I particles in patients with bone metastases
10.3969/j.issn.1002-1671.2024.02.031
- VernacularTitle:SPECT/CT融合显像在骨转移瘤患者125I粒子植入术后剂量验证中的应用价值
- Author:
Haijian LU
1
;
Yong ZHOU
;
Guyi TONG
;
Hongyan HU
;
Dingqin ZHUANG
Author Information
1. 浙江金华广福肿瘤医院核医学科,浙江 金华 321000
- Keywords:
bone metastases;
single photon emission computed tomography/computed tomography fusion imaging;
125I particle implantation;
predictive value
- From:
Journal of Practical Radiology
2024;40(2):306-310
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the value of single photon emission computed tomography/computed tomography(SPECT/CT)fusion imaging for post-implantation dose verification of 125I particles in patients with bone metastases.Methods Forty patients with metastatic bone tumors treated with 125I particles implantation were selected.Within 24 h after 125I particles implantation,patients underwent SPECT/CT fusion imaging and the radioactivity per unit(RPU)was calculated.The treatment planning system(TPS)was then used to obtain the isodose profiles of SPECT/CT fusion imaging results and to calculate the tumor target coverage.The patient's preoperative and postoperative 1 month clinical outcomes,including local tumour remission,pain assessment,quality of life and serum alkaline phosphatase(ALP)levels were compared,and a receiver operating characteristic(ROC)curve was applied to evaluate the predictive value of tumor target coverage on postoperative outcomes.Results The mean number of particles implanted in the target area was 32.52±12.87.Within 24 h of 125I particles implantation,SPECT/CT fusion imaging analysis confirmed a strong positive correlation between the RPU of the radioactive concentration area and the mean dose received by the patient(r=0.786,P<0.05).The predicted area under the curve(AUC)for local tumor remission,pain relief,quality of life improvement and change in ALP levels was 0.789,0.757,0.804 and 0.833,respectively.Conclusion SPECT/CT fusion imaging can be used for postoperative dose verification of 125I particles for metastatic bone tumors and has some predictive value for clinical outcomes.
